KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) EBIAT (2016 - 2025)

Historic EBIAT for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $844.6 million.

  • Regeneron Pharmaceuticals' EBIAT fell 796.56% to $844.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.5 billion, marking a year-over-year increase of 209.17%. This contributed to the annual value of $4.5 billion for FY2025, which is 209.17% up from last year.
  • Regeneron Pharmaceuticals' EBIAT amounted to $844.6 million in Q4 2025, which was down 796.56% from $1.5 billion recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' EBIAT registered a high of $3.1 billion during Q2 2021, and its lowest value of $722.0 million during Q1 2024.
  • For the 5-year period, Regeneron Pharmaceuticals' EBIAT averaged around $1.3 billion, with its median value being $1.1 billion (2021).
  • Per our database at Business Quant, Regeneron Pharmaceuticals' EBIAT skyrocketed by 24535.83% in 2021 and then crashed by 7250.31% in 2022.
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' EBIAT stood at $2.2 billion in 2021, then plummeted by 46.29% to $1.2 billion in 2022, then dropped by 3.13% to $1.2 billion in 2023, then dropped by 20.86% to $917.7 million in 2024, then dropped by 7.97% to $844.6 million in 2025.
  • Its EBIAT was $844.6 million in Q4 2025, compared to $1.5 billion in Q3 2025 and $1.4 billion in Q2 2025.